ABLS - ETF AI Analysis
Top Page
Abacus FCF Small Cap Leaders ETF (ABLS)
Rating:67Neutral
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has delivered strong gains so far this year and over the past three months, showing solid recent momentum.
Leading Winners in Top Holdings
Several of the largest positions, such as Argan, Oscar Health, Enova International, and Kontoor Brands, have posted strong year-to-date gains that support the fund’s overall results.
Diversified Sector Mix Within the U.S.
Holdings spread across health care, technology, financials, industrials, and other sectors help reduce the impact if any one industry runs into trouble.
Negative Factors
High U.S. Concentration
With almost all assets in U.S. companies, the fund offers little geographic diversification and is heavily tied to the U.S. economy.
Notable Weight in Weak Holdings
Some sizable positions like Collegium Pharmaceutical, Artisan Partners, and Harmony Biosciences have shown weak or negative performance this year, which can drag on returns if the trend continues.
Moderate Expense Ratio for a Small Fund
The fund’s expense ratio is not especially low and, combined with its relatively small asset base, means costs may weigh more on investor returns than in some larger, cheaper ETFs.
ABLS vs. SPDR S&P 500 ETF (SPY)
AUM442.02K
RegionNorth America
Expense Ratio0.39%
Beta0.73
IssuerAbacus
Inception DateFeb 18, 2025
Dividend YieldN/A
Asset ClassEquity
Index TrackedAbacus FCF Small Cap Leaders Index - Benchmark TR Gross
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume350
30 Day Avg. Volume1,818
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
25.89Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering50
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
ABLS Summary
The Abacus FCF Small Cap Leaders ETF (ABLS) is a fund that tracks the Abacus FCF Small Cap Leaders Index, focusing on smaller U.S. companies with strong profits and healthy cash flow. It holds a mix of businesses across health care, technology, finance, and industrials, including names like Qualys and Oscar Health. Someone might invest in ABLS to seek long-term growth and add diversification beyond large, well-known companies, while still focusing on financially solid firms. A key risk is that small-cap stocks can be more volatile than larger companies, so the price of this ETF can move up and down sharply with the market.
How much will it cost me?The Abacus FCF Small Cap Leaders ETF (ABLS) has an expense ratio of 0.39%, meaning you’ll pay $3.90 per year for every $1,000 invested. This is slightly higher than average for passively managed ETFs because it focuses on a niche area of small-cap stocks with strong financial metrics.
What would affect this ETF?The Abacus FCF Small Cap Leaders ETF could benefit from strong growth in the U.S. economy, particularly in sectors like technology and health care, which make up a significant portion of its holdings. However, it may face challenges if interest rates rise, as small-cap companies often rely on borrowing to fund growth, or if economic conditions weaken, which could impact consumer spending and industrial activity. Regulatory changes in key sectors like financials or health care could also influence performance positively or negatively.
ABLS Top 10 Holdings
ABLS is leaning hard into U.S. small caps with a clear tilt toward health care and tech, and a few names are doing the heavy lifting. Cybersecurity player Qualys and software firm Appian have been rising smartly, giving the fund a tech-powered boost. In health care, Harmony Biosciences and Oscar Health are climbing but with a bumpier, more mixed ride as profitability questions linger. On the flip side, Argan has been losing steam recently, and Collegium Pharmaceutical has been dragging the fund, underscoring how concentrated single-name swings can shape this small-cap portfolio.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Argan | 8.65% | $39.53K | $5.86B | 92.26% | 73 Outperform | |
| Oscar Health | 6.11% | $27.95K | $9.96B | 59.02% | 49 Neutral | |
| Enova International | 6.02% | $27.51K | $5.74B | 94.78% | 71 Outperform | |
| Artisan Partners | 4.67% | $21.36K | $3.37B | -10.87% | 73 Outperform | |
| Harmony Biosciences Holdings | 4.32% | $19.76K | $2.46B | 17.92% | 81 Outperform | |
| Qualys | 4.16% | $19.00K | $5.94B | 27.00% | 78 Outperform | |
| Healthcare Services | 3.53% | $16.13K | $1.50B | 37.15% | 72 Outperform | |
| Appian | 3.18% | $14.53K | $2.75B | 17.27% | 58 Neutral | |
| PJT Partners | 3.05% | $13.94K | $4.67B | 0.77% | 71 Outperform | |
| Kontoor Brands | 3.03% | $13.85K | $4.02B | -7.80% | 66 Neutral |
ABLS Technical Analysis
Negative
―
Price Trends
22.81
Negative
21.86
Negative
20.66
Positive
Market Momentum
-0.31
Positive
30.59
Neutral
3.75
Positive
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For ABLS, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 22.53, equal to the 50-day MA of 22.81, and equal to the 200-day MA of 20.66, indicating a neutral trend. The MACD of -0.31 indicates Positive momentum. The RSI at 30.59 is Neutral, neither overbought nor oversold. The STOCH value of 3.75 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ABLS.
ABLS Peer Comparison
Comparison Results
Performance Comparison
ABLS
Abacus FCF Small Cap Leaders ETF
21.31
0.67
3.25%
BKSE
BNY Mellon US Small Cap Core Equity ETF
―
―
―
AIMS
Acuitas Small Cap Active ETF
―
―
―
STXK
Strive 2000 ETF
―
―
―
RUSC
US Small Cap Equity Active ETF
―
―
―
SYZ
Lazard US Systematic Small Cap Equity ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents